ERBB2 and breast carcinoma: Multi-parametric molecular tests are now considered essential to the diagnostic management of luminal-type (ER+ve HER2-ve) early breast cancer and are included in key guidelines [1] as a pre-requisite for staging of breast cancer patients, to direct prognostication and to select patients for chemotherapy treatment [2, 3].